Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 42nd Annual...
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
December 05, 2023 06:00 ET
|
Amicus Therapeutics, Inc.
Crowley to Step Down from Amicus Board of Directors in March 2024 and Become Amicus Chairman Emeritus Michael Raab, Current Lead Independent Director, to Become Chairman of Amicus Board of Directors ...
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
November 08, 2023 07:00 ET
|
Amicus Therapeutics, Inc.
3Q 2023 Total Revenue of $103.5M, a 27% Increase Year-Over-Year and 22% at CER Galafold® Quarterly Revenue Surpasses $100M for the First Time Increasing FY 2023 Galafold® Revenue Growth Guidance...
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
November 01, 2023 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences...
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
October 27, 2023 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8,...
Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
October 03, 2023 07:00 ET
|
Amicus Therapeutics, Inc.
PRINCETON, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and four posters highlighting its development program for Pompe...
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
October 02, 2023 08:20 ET
|
Amicus Therapeutics, Inc.
Refinancing of Current $400M Debt at Lower Cost and Improved Amortization Schedule Blackstone to also Purchase $30M of Amicus Common Stock PRINCETON, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Amicus...
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
September 28, 2023 10:41 ET
|
Amicus Therapeutics, Inc.
Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults Living with Late-onset Pompe Disease Amicus...
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
September 01, 2023 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences...
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
August 29, 2023 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters across its development programs will be included at...